Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Working Capital to Net Assets Ratio
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd working capital to net assets ratio. Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has a Working Capital to Net Assets ratio of 29.0% as of June 2026. Working capital of CN¥231.55 Million (current assets of CN¥588.95 Million minus current liabilities of CN¥357.41 Million) is measured against net assets of CN¥799.00 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2025)
Working capital to net assets ratio of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025. This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 29.0%, reflecting working capital of CN¥231.55 Million against net assets of CN¥799.00 Million CNY. Explore 300534 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Working Capital to Net Assets Ratio by Year (2011–2025)
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Gansu Longshenrongfa Pharmaceutical Indu total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.2% | CN¥196.56 Million | CN¥781.08 Million | CN¥654.30 Million | CN¥457.74 Million | ▲ +3.6 pp |
| 2024 | 21.6% | CN¥157.15 Million | CN¥727.93 Million | CN¥676.50 Million | CN¥519.35 Million | ▼ -1.2 pp |
| 2023 | 22.7% | CN¥161.86 Million | CN¥711.51 Million | CN¥647.00 Million | CN¥485.14 Million | ▼ -13.3 pp |
| 2022 | 36.1% | CN¥275.19 Million | CN¥763.13 Million | CN¥402.59 Million | CN¥127.39 Million | ▲ +3.3 pp |
| 2021 | 32.8% | CN¥240.38 Million | CN¥732.84 Million | CN¥308.70 Million | CN¥68.32 Million | ▲ +1.7 pp |
| 2020 | 31.1% | CN¥229.62 Million | CN¥739.13 Million | CN¥333.10 Million | CN¥103.48 Million | ▲ +2.3 pp |
| 2019 | 28.7% | CN¥212.38 Million | CN¥738.88 Million | CN¥279.26 Million | CN¥66.88 Million | ▼ -2.0 pp |
| 2018 | 30.8% | CN¥221.84 Million | CN¥720.83 Million | CN¥273.66 Million | CN¥51.82 Million | ▲ +1.4 pp |
| 2017 | 29.4% | CN¥209.09 Million | CN¥712.19 Million | CN¥261.77 Million | CN¥52.68 Million | ▼ -5.1 pp |
| 2016 | 34.4% | CN¥242.17 Million | CN¥703.74 Million | CN¥282.25 Million | CN¥40.08 Million | ▼ -19.7 pp |
| 2015 | 54.2% | CN¥219.64 Million | CN¥405.57 Million | CN¥286.96 Million | CN¥67.32 Million | ▼ -23.7 pp |
| 2014 | 77.9% | CN¥282.85 Million | CN¥363.10 Million | CN¥326.15 Million | CN¥43.30 Million | ▼ -12.6 pp |
| 2013 | 90.5% | CN¥288.72 Million | CN¥318.92 Million | CN¥365.71 Million | CN¥76.99 Million | ▼ -6.3 pp |
| 2012 | 96.9% | CN¥166.10 Million | CN¥171.46 Million | CN¥262.04 Million | CN¥95.94 Million | ▲ +43.2 pp |
| 2011 | 53.7% | CN¥24.36 Million | CN¥45.35 Million | CN¥92.30 Million | CN¥67.95 Million | — |